VRDN · XBRL financial data

Viridian Therapeutics financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VRDN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Selling, general and administrative	—	—	—	95	61	95
General and administrative	13	26	35	95	61	—
Total operating expenses	111	83	136	255	299	434
Other operating income (expense)	—	—	—	(0)	(0)	(2)
Operating income (loss)	(110)	(80)	(134)	(254)	(299)	(363)
Interest income	—	—	—	18	32	27
Interest expense	—	—	1	1	3	5
Income tax expense (benefit)	—	—	—	—	—	0
Net income (loss)	(111)	(79)	(130)	(238)	(270)	(343)
Earnings per share, basic USD per share	(31.13)	(6.66)	(4.05)	(5.31)	—	—
Earnings per share, diluted USD per share	(31.13)	(6.66)	(4.05)	(5.31)	—	—
Weighted average shares, basic millions of shares	4	12	32	45	—	—
Weighted average shares, diluted millions of shares	4	12	32	45	—	—

Fiscal years (VRDN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	46	42	156	103	100	212
Short-term investments	82	155	—	—	—	—
Marketable securities	—	155	269	375	618	662
Prepaid and other current assets	2	3	7	9	21	20
Total current assets	130	200	431	486	738	894
Property and equipment, net	0	0	1	2	1	1
Right-of-use asset	0	2	2	2	2	2
Total assets	131	204	435	490	742	899
Accounts payable	1	2	14	2	2	9
Accrued liabilities	10	11	19	24	45	62
Current portion of long-term debt	—	—	—	0	0	—
Total current liabilities	11	14	33	27	48	71
Long-term debt	—	—	—	20	21	—
Lease liability, non-current	—	1	1	1	2	2
Total liabilities	11	16	40	48	71	177
Accumulated deficit	(279)	(358)	(488)	(726)	(996)	(1,338)
Total stockholders' equity	120	188	395	442	672	722
Total liabilities and equity	131	204	435	490	742	899
Common shares outstanding (cover page) millions of shares	7	26	43	63	81	102

Fiscal years (VRDN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(111)	(79)	(130)	(238)	(270)	(343)
Stock-based compensation	4	14	20	67	42	44
Depreciation and amortization	0	0	0	1	1	0
Net cash from operating activities	(30)	(55)	(94)	(184)	(232)	(276)
Purchases of property and equipment	0	0	1	1	1	0
Net cash from investing activities	(50)	(74)	(115)	(94)	(229)	(38)
Proceeds from issuing common stock	0	114	292	125	454	63
Proceeds from long-term debt	—	—	5	15	0	29
Net cash from financing activities	101	125	322	226	458	427
Net change in cash	21	(4)	113	(53)	(3)	113

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Viridian Therapeutics	173	26	not reported	113.6M	—	Q3 FY26 10-QSep 30, 2026
Akebia Therapeutics	156	49	3.5*	277.1M	—	Q2 FY26 10-QJun 30, 2026
Collegium Pharmaceutical	129	200	71*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Ardelyx	46	128	2.2*	251.4M	—	Q3 FY26 10-QSep 30, 2026
Neogen	172	223	13	218.3M	—	Q1 FY27 10-QAug 31, 2026
CorMedix	257	102	86*	77.9M	—	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	46	84	46*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Harrow	84	71	(9.8)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Novavax	191	57	(73)*	164.9M	9.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.